UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

Leukemia, 2014-05, Vol.28 (5), p.1033-1040

2014

Volltextzugriff (PDF)

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

Leukemia, 2015-12, Vol.29 (12), p.2452-2452

2015

Volltextzugriff (PDF)

First two cases of immune hemolytic anemia associated with ceftizoxime

Transfusion (Philadelphia, Pa.), 1999-08, Vol.39 (8), p.838-844

1999

Volltextzugriff (PDF)

Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions

Therapeutics and clinical risk management, 2016-01, Vol.12 (Issue 1), p.201-208

2016

Volltextzugriff (PDF)

Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

Leukemia, 2015-12, Vol.29 (12), p.2452-2452

2015

Volltextzugriff (PDF)

Use of a tumor-cell enrichment column for the enhanced detection of minimal residual disease in the BM or apheresis peripheral blood transplant products of breast-cancer patients

Cytotherapy (Oxford, England), 1999-01, Vol.1 (5), p.367-376

1999

Volltextzugriff (PDF)

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)

Journal of hematology and oncology, 2017-06, Vol.10 (1), p.131-131, Article 131

2017

Volltextzugriff (PDF)

Etoposide and cytarabine as an effective and safe cytoreductive regimen for relapsed or refractory acute myeloid leukemia

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6539-6539

2011

Volltextzugriff (PDF)

An analysis of high ferritin levels before allogeneic hematopoietic cell transplantation (AlloHCT): A retrospective study to evaluate prognostic factors in patients (pts) undergoing AlloHCT for myelodysplasia

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6562-6562

2011

Volltextzugriff (PDF)

A case report of sarcoma regression in a patient with MDS treated with lenalidomide

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.20535-20535

2007

Volltextzugriff (PDF)

Multicenter analysis of 81 solid organ transplant (SOT) recipients with posttransplantation lymphoproliferative disease (PTLD): Examination of survival and prognostic factors

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.8510-8510

2009

Volltextzugriff (PDF)

Myeloproliferative Neoplasms with Subsequent Development of Chronic Myelogenous Leukemia: A Case Series

Clinical Hematology and Research, 2020-05, Vol.3 (1)

2020

Volltextzugriff (PDF)

Outcomes for Patients (Pts) with Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) with del5q Aged < 65 Years Treated with Lenalidomide (LEN) in MDS-003 and MDS-004: A Retrospective Combined Analysis

BLOOD, 2011, Vol.118 (21), p.750

2011

Volltextzugriff (PDF)

RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia

Nature communications, 2018-03, Vol.9 (1), p.1163-16, Article 1163

2018

Volltextzugriff (PDF)

Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry

Annals of hematology, 2020-07, Vol.99 (7), p.1505-1514

2020

Volltextzugriff (PDF)

Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia

Journal of clinical oncology, 2010-01, Vol.28 (3), p.437-444

2010

Volltextzugriff (PDF)

Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria

Hematology, 2024-12, Vol.29 (1)

2024

Volltextzugriff (PDF)

Transfusion Independence Achieved with Combination Fedratinib and Luspatercept in an Elderly Man with Heavily Pretreated Intermediate-2 Risk Primary Myelofibrosis

Case reports in oncology, 2022-01, Vol.15 (1), p.126-132

2022

Volltextzugriff (PDF)

Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US

Blood, 2019-11, Vol.134 (Supplement_1), p.3407-3407

2019

Volltextzugriff (PDF)

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Haematologica (Roma), 2015-04, Vol.100 (4), p.479-488

2015

Volltextzugriff (PDF)

Author Correction: RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia

Nature communications, 2018-06, Vol.9 (1), p.2286-1, Article 2286

2018

Volltextzugriff (PDF)

A Novel Patient Reported Outcome Instrument Assessing the Symptoms of Paroxysmal Nocturnal Hemoglobinuria

Blood, 2019-11, Vol.134 (Supplement_1), p.385-385

2019

Volltextzugriff (PDF)

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis: Phase 3 Long-Term Data

Blood, 2023-11, Vol.142 (Supplement 1), p.576-576

2023

Volltextzugriff (PDF)

Creating a Variant Database for the American Society of Hematalogy By Consensus Variant Classification of Common Genes Associated with Hematologic Malignancies

Blood, 2020-11, Vol.136 (Supplement 1), p.4-5

2020

Volltextzugriff (PDF)

1 – 25 von 52

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(48)

Publikationsform

Sprache

Englisch
(52)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(18)
Life Sciences & Biomedicine
(17)
Humans
(13)
Hematology
(11)
Female
(10)
Male
(8)
Middle Aged
(8)
Oncology
(8)
Treatment Outcome
(8)
Aged
(7)
Adult
(5)
Biological And Medical Sciences
(5)
Medical Sciences
(5)
Myelodysplastic Syndromes - Drug Therapy
(5)
Aged, 80 And Over
(4)
Leukemia
(4)
Myelodysplastic Syndromes
(4)
Myelodysplastic Syndromes - Genetics
(4)
Patients
(4)
Risk Factors
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

First two cases of immune hemolytic anemia associated with ceftizoxime

Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions

Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

Use of a tumor-cell enrichment column for the enhanced detection of minimal residual disease in the BM or apheresis peripheral blood transplant products of breast-cancer patients

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)

Etoposide and cytarabine as an effective and safe cytoreductive regimen for relapsed or refractory acute myeloid leukemia

An analysis of high ferritin levels before allogeneic hematopoietic cell transplantation (AlloHCT): A retrospective study to evaluate prognostic factors in patients (pts) undergoing AlloHCT for myelodysplasia

A case report of sarcoma regression in a patient with MDS treated with lenalidomide

Multicenter analysis of 81 solid organ transplant (SOT) recipients with posttransplantation lymphoproliferative disease (PTLD): Examination of survival and prognostic factors

Myeloproliferative Neoplasms with Subsequent Development of Chronic Myelogenous Leukemia: A Case Series

Outcomes for Patients (Pts) with Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) with del5q Aged < 65 Years Treated with Lenalidomide (LEN) in MDS-003 and MDS-004: A Retrospective Combined Analysis

RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia

Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry

Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia

Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

Transfusion Independence Achieved with Combination Fedratinib and Luspatercept in an Elderly Man with Heavily Pretreated Intermediate-2 Risk Primary Myelofibrosis

Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Author Correction: RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia

A Novel Patient Reported Outcome Instrument Assessing the Symptoms of Paroxysmal Nocturnal Hemoglobinuria

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis: Phase 3 Long-Term Data

Creating a Variant Database for the American Society of Hematalogy By Consensus Variant Classification of Common Genes Associated with Hematologic Malignancies

Suchergebnisse filtern